Adaptimmune to Host Virtual Investor Day on Friday, November 20th
November 12 2020 - 8:00AM
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell
therapy to treat cancer, will host a
virtual Investor Day on November 20, 2020 at
8AM EST/ 1PM GMT. A link to register is available HERE
and further details are on the Investor Relations tab of
the Adaptimmune website.
The Company plans to showcase the market potential
for its SPEAR T-cell portfolio as well as provide details about its
early stage pipeline with multiple cell therapies beyond its
current autologous TCR T-cell products. Presentations will be given
by Adaptimmune’s Senior Leadership Team in addition to
Dr. Dejka Araujo from the Department of Sarcoma Medical Oncology,
Division of Cancer Medicine of the MD Anderson Cancer Center.
About Adaptimmune Adaptimmune is a
clinical-stage biopharmaceutical company focused on the development
of novel cancer immunotherapy products for people with cancer. The
Company’s unique SPEAR® (Specific Peptide Enhanced Affinity
Receptor) T-cell platform enables the engineering of T-cells to
target and destroy cancer across multiple solid tumors.
Forward-Looking
Statements This release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995 (PSLRA). These forward-looking statements
involve certain risks and uncertainties. Such risks and
uncertainties could cause our actual results to differ materially
from those indicated by such forward-looking statements, and
include, without limitation: the success, cost and timing of our
product development activities and clinical trials and our ability
to successfully advance our TCR therapeutic candidates through the
regulatory and commercialization processes. For a further
description of the risks and uncertainties that could cause our
actual results to differ materially from those expressed in these
forward-looking statements, as well as risks relating to our
business in general, we refer you to our Quarterly Report on Form
10-Q filed with the SEC on November 5, 2020, and our other SEC
filings. The forward-looking statements contained in this press
release speak only as of the date the statements were made and we
do not undertake any obligation to update such forward-looking
statements to reflect subsequent events or circumstances.
Media Relations:
Sébastien Desprez — VP, Communications and Investor
RelationsT: +44 1235 430 583M: +44 7718 453
176Sebastien.Desprez@adaptimmune.com
Investor Relations:
Juli P. Miller, Ph.D. — Senior Director, Investor
RelationsT: +1 215 825 9310M: +1 215 460
8920Juli.Miller@adaptimmune.com
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Sep 2023 to Sep 2024